Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Drug Delivery Systems: Introduction01:23

Oral Drug Delivery Systems: Introduction

279
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
279
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

308
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
308
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

222
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
222
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

406
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
406
Factors Affecting Dissolution: Particle Size and Effective Surface Area01:23

Factors Affecting Dissolution: Particle Size and Effective Surface Area

1.9K
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
1.9K
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

352
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
352

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced view totally extraperitoneal (eTEP) repair for ventral hernia: A prospective analysis of peri-operative outcomes, functional recovery, and cost effectiveness.

Journal of minimal access surgery·2026
Same author

Pathogenic Modulation of Organelle Crosstalk in <i>Helicobacter pylori</i>-Associated Neurodegeneration.

ACS chemical neuroscience·2026
Same author

Redox- and Photo-Responsive Fe<sup>3+/2+</sup>-Cross-Linked Carboxymethyl Cellulose Methacrylate Dissipative Gels: Synthesis and Applications.

ACS applied materials & interfaces·2026
Same author

Biotherapeutic strategies for quorum quenching in Salmonella Typhi: a review.

Archives of microbiology·2026
Same author

Pulmonary exacerbations in cystic fibrosis after fatherhood with and without CFTR modulators.

Respiratory medicine·2026
Same author

Assays for the optimization of drug discovery in visceral leishmaniasis.

3 Biotech·2026

Related Experiment Video

Updated: May 5, 2026

Formulation and Characterization of Bioactive Agent Containing Nanodisks
07:58

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

1.8K

Solid Pro-Nano Lipid Oral Formulations for Cannabidiol (CBD).

Awanish Kumar1, Ayala Bar-Hai1, Muhammad AbdEl-Haq1

  • 1Institute of Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 91120, Israel.

Pharmaceutics
|May 4, 2026
PubMed
Summary

New solid pro-nano lipid (SPNL) formulations enhance oral cannabidiol (CBD) bioavailability in rats. These stable, solvent-free systems offer a safer alternative for delivering lipophilic drugs orally.

Keywords:
cannabidiol (CBD)liquid PNL (LPNL)long-term stabilityoral bioavailabilitypharmacokinetics (PK)solid pro-nano lipids (SPNL)

More Related Videos

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

1.4K
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

8.4K

Related Experiment Videos

Last Updated: May 5, 2026

Formulation and Characterization of Bioactive Agent Containing Nanodisks
07:58

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

1.8K
Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

1.4K
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

8.4K

Area of Science:

  • Pharmaceutical Sciences
  • Drug Delivery Systems
  • Nanotechnology

Background:

  • Development of novel solid pro-nano lipid (SPNL) oral formulations.
  • Investigation focused on enhancing oral bioavailability of cannabidiol (CBD).

Purpose of the Study:

  • To prepare and characterize SPNL formulations for oral drug delivery.
  • To evaluate the pharmacokinetic performance of SPNL and LPNL formulations in rats.
  • To assess the stability of these novel formulations.

Main Methods:

  • Preparation of SPNL formulations containing up to 40% w/w CBD.
  • Characterization of particle size upon dispersion in aqueous media (<200 nm).
  • Pharmacokinetic studies in Wistar rats following oral administration of SPNL and LPNL.
  • Stability testing of formulations at room temperature for 3 months.

Main Results:

  • SPNL and LPNL formulations demonstrated rapid CBD absorption and high Cmax values in rats.
  • Formulations exhibited stability at room temperature for at least 3 months.
  • Lesser CBD stability observed with mesoporous silica particles (Neusilin US2, SYLOID 244 FP).

Conclusions:

  • SPNL formulations are solvent-free, offering a safer alternative to traditional SNEDDS systems.
  • These solid lipid-based formulations show potential for delivering other lipophilic drugs.
  • The developed formulations provide enhanced oral bioavailability for CBD.